NEWS

12DNA is proud to celebrate its 10th anniversary this year. Over the past decade, the company has pioneered advancements in gene editing technology, developed groundbreaking therapies, and established itself as a leader in the field of genetic medicine. This anniversary is an opportunity to reflect on 12DNA’s accomplishments and its vision for a future where genetic diseases are a thing of the past.   para

Unveiled its commitment to achieving carbon neutrality by 2030 and launched its Sustainable Lab Practices initiative. The program focuses on reducing energy consumption, minimizing waste, and promoting sustainable practices within its laboratories and operations. This initiative underscores 12DNA’s dedication to environmental responsibility and its role in building a sustainable future.

Today announced a $50 million investment in a new state-of-the-art research and development facility dedicated to advancing CRISPR technology. This investment will expand the company’s research capabilities and accelerate the development of new gene editing tools and therapies for various diseases.

12DNA today announced record-breaking results for the third quarter of 2023. The company achieved significant growth in revenue and profitability, driven by strong demand for its gene editing services and partnerships with leading pharmaceutical companies. This success reflects 12DNA’s position as a leader in the rapidly growing gene editing market.

12DNA is pleased to announce the appointment of Dr. Emily Carter as its new Chief Executive Officer. With a distinguished career in genetics research and industry leadership, Dr. Carter brings a wealth of expertise and strategic vision to guide 12DNA towards continued growth and innovation in the field of gene editing and genetic medicine.

Recently hosted a successful charity gala that raised $2 million in support of the Rare Genomics Institute. The event brought together industry leaders, scientists, and philanthropists for an evening of awareness and fundraising, demonstrating 12DNA’s dedication to supporting research for rare genetic diseases.